NCT03901963 2026-04-13
AURIGA
Janssen Research & Development, LLC
Phase 3 Active not recruiting
Clinical Trials
14 trialsNCT04181827 2026-04-13
CARTITUDE-4
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05083169 2026-04-13
MajesTEC-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05455320 2026-04-13
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03652064 2026-04-08
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04975997 2026-04-03
EXCALIBER-RRMM
Celgene
Phase 3 Active not recruiting
NCT05257083 2026-03-17
CARTITUDE-6
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT04071457 2025-09-15
DRAMMATIC
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT06868667 2025-05-09
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06868654 2025-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT03836014 2024-12-06
CONFIRM
Assistance Publique - Hôpitaux de Paris
Phase 3 Active not recruiting
NCT04246047 2024-10-24
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT03651128 2022-12-15
KarMMa-3
Celgene
Phase 3 Active not recruiting